Influence of baseline lipids on effectiveness of pravastatin in the CARE trial

Journal of the American College of Cardiology

Volumn 33, Issue 1, 1999, Pages 125-130

  Pfeffer, Marc A ^a   Sacks, Frank M ^b   Moyé, Lemuel A ^c   East, Cara ^d   Goldman, Steven ^e   Nash, David T ^f   Rouleau, Jacques R ^g   Rouleau, Jean Lucien ^a   Sussex, Bruce A ^b   Theroux, Pierre ^c   Vanden Belt, Ron J ^d   Braunwald, Eugene ^e,h  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c BAYLOR UNIVERSITY   (United States)

^d SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^e SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^f LAVAL UNIVERSITY   (Canada)

^g MONTREAL HEART INSTITUTE   (Canada)

^h Health Sciences Centre St John's   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CHOLESTEROL, LDL; COHORT STUDIES; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LIPIDS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PRAVASTATIN; RECURRENCE; SURVIVAL RATE; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 0032920672     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00522-1     Document Type: Article

References (26)

1. Stamler J, Wentworth D, Neaton JD, for the MRFIT Research Group. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). J Am Med Assoc 1986;256:2823-8.
2. LaRosa JC, Hunninghake D, Bush D, et al., the Task Force on Cholesterol Issues, American Heart Association. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. Circulation 1990;81:1721-33.
3. Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without pre-existing cardiovascular disease. N Engl J Med 1990;322:1700-7.
4. Rosengren A, Hagman M, Wedel H, Wihelmsen L. Serum cholesterol and long-term prognosis in middle-aged men with myocardial infarction and angina pectoris. A 16-year follow-up of the Primary Prevention Study in Göteborg, Sweden. Eur Heart J 1997;18:754-61.
5. Rose G, Hamilton PS, Keen H, Reid DD, McCartney P, Jarrett RJ. Myocardial ischaemia, risk factors and death from coronary heart disease. Lancet 1977;1:105-9.
6. Wong ND, Wilson PW, Kannel WB. Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study. Ann Intern Med 1991;115:687-93.
7. Stampfer MJ, Sacks FM, Salvini S, Willen WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991;325:373-81.
8. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. J Am Med Assoc 1986;256:2835-8.
9. Gordon DJ. Cholesterol lowering and total mortality. In: Rifkind BM, editor. Contemporary Issues in Cholesterol Lowering: Clinical and Population Aspects. New York: Marcel Dekker, 1994.
10. Holme I. Cholesterol reduction and its impact on coronary artery disease and total mortality. Am J Cardiol 1995;76:10C-7C.
11. Oliver MF. Doubts about preventing coronary heart disease. BMJ 1992;304:393-4.
12. Davey Smith G, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ 1992;304:431-4.
13. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
14. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
15. Pederson T, Kjekshus J, Berg K, et al. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995;345:1274-5.
16. Sacks FM, Pfeffer MA, Moyé LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
17. Pfeffer MA, Sacks FM, Moyé LA, et al. Cholesterol and recurrent events: a secondary prevention trial for normolipidemic patients. Am J Cardiol 1995;76:98C-106C.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958;53:457-81.
19. Johnson CL, Rifkind BM, Sempos CT, et al. Declining serum total cholesterol levels among US adults. The National Health and Nutrition Examination Surveys. J Am Med Assoc 1993;269:3002-8.
20. Kännel WB. Range of serum cholesterol values in the population developing coronary heart disease. Am J Cardiol 1995;76:69C-77C.
21. Miller M, Seidler A, Kwiterovich PO, Pearson TA. Long-term predictors of subsequent cardiovascular events with coronary artery disease and "desirable" levels of plasma total cholesterol. Circulation 1992;86:1165-70.
22. Holme I. Relation of coronary heart disease incidence and total mortality to plasma cholesterol reduction in randomized trials: use of meta-analysis. Br Heart J 1993;69:S42-7.
23. The LIPID Study Group. Design features and baseline characteristics of the LIPID (Long-term Intervention with Pravastatin in Ischemic Disease) study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris. Am J Cardiol 1995;76:474-9.
24. Rubins HB, Robins SJ, Iwane MK, et al. Rationale and design of the Department of Veterans Affairs High-density-lipoprotein cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. Am J Cardiol 1993;71:45-52.
25. The Bezafibrate Infarction Prevention (BIP) Study Group. Lipids and lipoproteins in symptomatic coronary heart disease: distribution, intercorrelations, and significance for risk classification in 6,700 men and 1,500 women. Circulation 1992;86:839-48.
26. Stampfer MJ, Rimm EB. Folate and cardiovascular disease: why we need a trial now [editorial]. J Am Med Assoc 1996;275:1929-30.